

**LILRA3 Blocking Peptide (C-term)**

Synthetic peptide

Catalog # BP20443b

**Specification****LILRA3 Blocking Peptide (C-term) - Product Information**Primary Accession [Q8N6C8](#)**LILRA3 Blocking Peptide (C-term) - Additional Information**

Gene ID 11026

**Other Names**

Leukocyte immunoglobulin-like receptor subfamily A member 3, CD85 antigen-like family member E, Immunoglobulin-like transcript 6, ILT-6, Leukocyte immunoglobulin-like receptor 4, LIR-4, Monocyte inhibitory receptor HM43/HM31, CD85e, LILRA3, ILT6, LIR4

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**LILRA3 Blocking Peptide (C-term) - Protein Information**

Name LILRA3

Synonyms ILT6, LIR4

**Function**

Acts as soluble receptor for class I MHC antigens. Binds both classical and non-classical HLA class I molecules but with

**LILRA3 Blocking Peptide (C-term) - Background**

May act as soluble receptor for class I MHC antigens.

**LILRA3 Blocking Peptide (C-term) - References**

Zhang Z., et al. Protein Sci. 13:2819-2824(2004).  
Arm J.P., et al. J. Immunol. 159:2342-2349(1997).  
Borges L., et al. J. Immunol. 159:5192-5196(1997).  
Norman P.J., et al. Immunogenetics 55:165-171(2003).

reduced affinities compared to LILRB1 or LILRB2. Binds with high affinity to the surface of monocytes, leading to abolish LPS-induced TNF-alpha production by monocytes.

**Cellular Location**

Secreted.

**Tissue Location**

Detected in B-cells, and at lower levels in natural killer (NK) cells. Detected in peripheral blood monocytes and lung

**LILRA3 Blocking Peptide (C-term) -  
Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)